The role of progesterone and the progesterone receptor in human reproduction and cancer

References

• Corner GW, Allen WM. Physiology of the corpus luteum. 1929. Am. J. Obstet. Gynecol. 193, 1574; discussion 1575 (2005).
   PubMed Web of Science ®Google Scholar
• Jones GS. Some newer aspects of management of infertility. JAMA 141, 1123–1129 (1949).
   PubMed Web of Science ®Google Scholar
• Baulieu EE. Contragestion and other clinical applications of RU-486, an antiprogesterone at the receptor. Science 245, 1351–1357 (1989).
   PubMed Web of Science ®Google Scholar
• Noyes RW, Hertig AI, Rock J. Dating the endometrial biopsy. Fertil. Steril. 1, 3–35 (1950).
   Web of Science ®Google Scholar
• Meyer WR, Castelbaum AJ, Somkuti Set al. Hydrosalpinges adversely affect markers of endometrial receptivity. Hum. Reprod. 12, 1393–1398 (1997).
   PubMed Web of Science ®Google Scholar
• Savaris RF, Pedrini JL, Flores R, Fabris G, Zettler CG. Expression of alpha 1 and beta 3 integrins subunits in the endometrium of patients with tubal phimosis or hydrosalpinx. Fertil. Steril. 85, 188–192 (2006).
   PubMed Web of Science ®Google Scholar
• Daftary GS, Kayisli U, Seli E, Bukulmez O, Arici A, Taylor HS. Salpingectomy increases peri-implantation endometrial HOXA-10 expression in women with hydrosalpinx. Fertil. Steril. 87, 367–372 (2007).
   PubMed Web of Science ®Google Scholar
• Yashinaga K. Uterine receptivity for blastocyst implantation. Ann. N. Y. Acad. Sci. 541, 424–431 (1988).
   PubMed Web of Science ®Google Scholar
• Lessey BA. Assessment of endometrial receptivity. Fertil. Steril. 96, 522–529 (2011).
   PubMed Web of Science ®Google Scholar
• Aplin JD. MUC-1 glycosylation in endometrium: possible roles of the apical glycocalyx at implantation. Hum. Reprod. 14(Suppl. 2), 17–25 (1999).
   PubMed Web of Science ®Google Scholar
• De Souza MM, Surveyor GA, Price REet al. MUC1/episialin: a critical barrier in the female reproductive tract. J. Reprod. Immunol. 45, 127–158 (1999).
   PubMed Web of Science ®Google Scholar
• Surveryor GA, Gendler SJ, Pemberton Let al. Expression and steroid hormonal control of Muc-1 in the mouse uterus. Endocrinology 136, 3639–3647 (1995).
   PubMed Web of Science ®Google Scholar
• Margarit L, Gonzalez D, Lewis PDet al. L-selectin ligands in human endometrium: comparison of fertile and infertile subjects. Hum. Reprod. 24, 2767–2777 (2009).
   PubMed Web of Science ®Google Scholar
• Wang B, Sheng JZ, He RH, Qian YL, Jin F, Huang HF. High expression of L-selectin ligand in secretory endometrium is associated with better endometrial receptivity and facilitates embryo implantation in human being. Am. J. Reprod. Immunol. 60, 127–134 (2008).
   PubMed Web of Science ®Google Scholar
• Fukuda MN, Sato T, Nakayama Jet al. Trophinin and tastin, a novel cell adhesion molecule complex with potential involvement in embryo implantation. Genes. Dev. 9, 1199–1210 (1995).
   PubMed Web of Science ®Google Scholar
• Albelda SM, Buck CA. Integrins and other cell adhesion molecules. FASEB J. 4, 2868–2880 (1990).
   PubMed Web of Science ®Google Scholar
• Achache H, Revel A. Endometrial receptivity markers, the journey to successful embryo implantation. Hum. Reprod. Update 12, 731–746 (2006).
   PubMed Web of Science ®Google Scholar
• Creus M, Balasch J, Ordi Jet al. Integrin expression in normal and out-of-phase endometria. Hum. Reprod. 13, 3460–3468 (1998).
   PubMed Web of Science ®Google Scholar
• Surrey ES, Lietz AK, Gustofson RL, Minjarez DA, Schoolcraft WB. Does endometrial integrin expression in endometriosis patients predict enhanced in vitro fertilization cycle outcomes after prolonged GnRH agonist therapy. Fertil. Steril. 93, 646–651 (2010).
   PubMed Web of Science ®Google Scholar
• Enders AC, Nelson DM. Pinocytotic activity of the uterus of the rat. Am. J. Anat. 138, 277–299 (1973).
   PubMedGoogle Scholar
• Quinn CE, Ryan E, Claessens EAet al. The presence of pinopodes in the human endometrium does not delineate the implantation window. Fertil. Steril. 87, 1015–1021 (2007).
   PubMed Web of Science ®Google Scholar
• Usadi RS, Groll JM, Lessey BAet al. Endometrial development and function in experimentally induced luteal phase deficiency. J. Clin. Endocrinol. Metab. 93, 4058–4064 (2008).
   PubMed Web of Science ®Google Scholar
• Matsuzaki S, Canis M, Darcha C, Pouly JL, Mage G. HOXA-10 expression in the mid-secretory endometrium of infertile patients with either endometriosis, uterine fibromas or unexplained infertility. Hum. Reprod. 24, 3180–3187 (2009).
   PubMed Web of Science ®Google Scholar
• Szczepanska M, Wirstiein P, Luczak M, Jagodzinski PP, Skrzypczak J. Reduced expression of HOXA-10 in the midluteal endometrium from infertile women with minimal endometriosis. Biomed. Pharmacother. 64, 697–705 (2010).
   PubMed Web of Science ®Google Scholar
• Cakmak H, Taylor HS. Molecule mechanisms of treatment resistance in endometriosis: the role of progesterone-hox gene interactions. Semin. Reprod. Med. 28, 69–74 (2010).
   PubMed Web of Science ®Google Scholar
• Young SL, Lessey BA, Balthazar Uet al. Defining the relationship between progesterone dose, endometrial histology and gene expression using an in vivo luteal phase defect model. Reprod. Sci. 18, 273A (2011).
   Web of Science ®Google Scholar
• Dominguez F, Garrido-Gomez T, Lopez JAet al. Proteomic analysis of the human receptive versus non-receptive endometrium using differential in-gel electrophoresis and MALDI-MS unveils stathmin 1 and annexin A2 as differentially regulated. Hum. Reprod. 24, 2607–2617 (2009).
   PubMed Web of Science ®Google Scholar
• Parmar T, Gadkar-Sable S, Savardekar Iet al. Protein profiling of human endometrial tissues in the midsecretory and proliferative phases of the menstrual cycle. Fertil. Steril. 92, 1091–1103 (2009).
   PubMed Web of Science ®Google Scholar
• DeSouza L, Diehl G, Yang ECet al. Proteomic analysis of the proliferative and secretory phases of the human endometrium: protein identification and differential protein expression. Proteomics 5, 270–281 (2005).
   PubMed Web of Science ®Google Scholar
• Wetendorf M, DeMayo FJ. The progesterone receptor regulates implantation, decidualization, and glandular development via a complex paracrine signaling network. Mol. Cell Endocrinol. 357, 108–118 (2012).
   PubMed Web of Science ®Google Scholar
• Lachmann M, Gelbmann D, Kalman Eet al. PIBF (progesterone-induced blocking factor) is overexpressed in highly proliferating cells and associated with the centrosome. Int. J. Cancer 112, 51–60 (2004).
   PubMed Web of Science ®Google Scholar
• Polgar B, Kispal GY, Lachmann Met al. Molecular cloning and immunological characterization of a novel cDNA coding for PIBF. J. Immunol. 171, 5956–5963 (2003).
   PubMed Web of Science ®Google Scholar
• Szekeres-Bartho J, Hadnagy J, Pacsa AS. The suppressive effect of progesterone on lymphocyte cytotoxicity: unique progesterone sensitivity of pregnancy lymphocytes. J. Reprod. Immunol. 7, 121–128 (1985).
   PubMed Web of Science ®Google Scholar
• Szekeres-Bartho J, Autran B, Debre P, Andreu G, Denver L, Chaouat G. Immunoregulatory effects of a suppressor factor from healthy pregnant women’s lymphocytes after progesterone induction. Cell Immunol. 122, 281–294 (1989).
   PubMed Web of Science ®Google Scholar
• Szekeres-Bartho J, Szekeres GY, Debre P, Autran B, Chaouat G. Reactivity of lymphocytes to a progesterone receptor-specific monoclonal antibody. Cell Immunl. 125, 273–283 (1990).
   PubMed Web of Science ®Google Scholar
• Polgar B, Barakony A, Xinos I, Szekeres-Bartho J. The role of γ/δ TCR positive cells in pregnancy. Am. J. Reprod. Immunol. 41, 239–244 (1999).
   PubMed Web of Science ®Google Scholar
• Szekeres-Bartho J, Barakonyi A, Polgar Bet al. The role of γ/δ T cells in progesterone-mediated immunomodulation during pregnancy: a review. Am. J. Reprod. Immunol. 42, 44–48 (1999).
   PubMed Web of Science ®Google Scholar
• Hansen KA, Opsahl MS, Nieman LK, Baker JR Jr, Klein TA. Natural killer cell activity from the pregnant subjects is modulated by RU 486. Am. J. Obstet. Gynecol. 166, 87–90 (1992).
   PubMed Web of Science ®Google Scholar
• Szekeres-Bartho J, Kilar F, Falkay G, Csernus V, Torok A, Pacsa AS. Progesterone-treated lymphocytes of healthy pregnant women release a factor inhibiting cytotoxicity and prostaglandin synthesis. Am. J. Reprod. Immunol Microbiol. 9, 15–18 (1985).
   PubMed Web of Science ®Google Scholar
• Ivanova-Todorova E, Kyurkchiev DS, Nalbanski A, Timeva T, Shterev A, Kyurkchiev SD. Production and characterization of a novel monoclonal antibody against progesterone-induced blocking factor (PIBF). J. Reprod. Immunol. 78, 94–101 (2008).
   PubMed Web of Science ®Google Scholar
• Szekeres-Bartho J, Weill BJ, Mike G, Houssin D, Chaouat G. Progesterone receptors in lymphocytes of liver-transplanted and transfused patients. Immunol. Lett. 22, 259–261 (1989).
   PubMed Web of Science ®Google Scholar
• Chiu L, Nishimura M, Ishi Yet al. Enhancement of the expression of progesterone receptor on progesterone-treated lymphocytes after immunotherapy in unexplained recurrent spontaneous abortion. Am. J. Reprod. Immunol. 35, 552–557 (1996).
   PubMed Web of Science ®Google Scholar
• Check JH, Arwitz M, Gross J, Peymer M, Szekeres-Bartho J. Lymphocyte immunotherapy (LI) increases serum levels of progesterone-induced blocking factor. Am. J. Reprod. Immunol. 37, 17–20 (1997).
   PubMed Web of Science ®Google Scholar
• Check JH, Szekeres-Bartho J, O'Shaughnessy A. Progesterone-induced blocking factor seen in pregnancy lymphocytes soon after implantation. Am. J. Reprod. Immunol. 35, 277–280 (1996).
   PubMed Web of Science ®Google Scholar
• Check JH, Arwitz M, Gross J, Szekeres-Bartho J, Wu CH. Evidence that the expression of progesterone-induced blocking factor by maternal T-lymphocytes is positively correlated with conception. Am. J. Reprod. Immunol. 38(1), 6–8 (1997).
   PubMed Web of Science ®Google Scholar
• Cohen R, Check JH, DiAntonio A, Srivastava MD. Progesterone-induced blocking factor (PIBF), an immunosuppressive protein that inhibits natural killer (NK) cell cytolytic activity, detected 3 days after embryo transfer (ET). Fertil. Steril. 98(Suppl. 3), S28 (2012).
   Web of Science ®Google Scholar
• Check JH, Cohen R, Jaffe A, Tran J, Sarumi M. An allogeneic stimulus is not a prerequisite for the expression of the immunomodulatory protein the progesterone-induced blocking factor (PIBF). Am. J. Reprod. Immunol, ISIR, Boston, MA (2013).
   Google Scholar
• Check JH, Cohen R, DiAntonio A, Check D. The demonstration that the immunomodulatory protein the progesterone-induced blocking factor significantly rises in males with short term progesterone exposure provides new insights into the immunology of pregnancy. Fertil. Steril. 99(3), S22–S23 (2013).
   Web of Science ®Google Scholar
• Faust Z, Laskarin G, Rukavina Det al. Progesterone-induced blocking factor inhibits degranulation of NK cells. Am. J. Reprod. Immunol 42, 71 (1999).
   PubMed Web of Science ®Google Scholar
• Kozma N, Halasz M, Polgar Bet al. PIBF activates STAT6 via binding to a novel IL-4 receptor. J. Immunol. 176, 819–826 (2006).
   PubMed Web of Science ®Google Scholar
• Szekeres-Bartho J, Wegmann TG. A progesterone-dependent immuno-modulatory protein alters the Th1/Th2 balance. J. Reprod. Immunol. 31, 81–95 (1996).
   PubMed Web of Science ®Google Scholar
• Wegmann TG, Lin H, Guilbert L, Mosmann TR. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a Th2 phenomenon? Immunol. Today 14, 353–356 (1993).
   PubMedGoogle Scholar
• Raghupathy R. Th-1 type immunity is incompatible with successful pregnancy. Immunol. Today 18, 478–482 (1997).
   PubMedGoogle Scholar
• Raghupathy R, Al Mutawa E, Makhseed Met al. Modulation of cytokine production by dydrogesterone in lymphocytes from women with recurrent abortion. BJOG 112, 1096–1101 (2005).
   PubMed Web of Science ®Google Scholar
• Raghupathy R, Al Mutawa E, Maksheed M, Azizieh F, Szekeres-Bartho J. Redirection of cytokine production by lymphocytes from women with pre-term delivery by dydrogesterone. Am. J. Reprod. Immunol 58, 31–38 (2007).
   PubMed Web of Science ®Google Scholar
• Raghupathy R, Makhseed M, Azizieh F, Omu A, Gupta M, FArhat R. Cytokine production by maternal lymphocytes during normal human pregnancy and in unexplained recurrent spontaneous abortion. Hum. Reprod. 15, 713–718 (2000).
   PubMed Web of Science ®Google Scholar
• Yao MW, Lim H, Schust DJet al. Gene expression profiling reveals progesterone-mediated cell cycle and immunoregulatory roles of HOXA-10 in the preimplantation uterus. Mol. Endocrol. 17, 610–627 (2003).
   PubMedGoogle Scholar
• Sentman CL, Meadows SK, Wira CR, Eriksson M. Recruitment of uterine NK cells. Induction of CXC chemokine ligands 10 and 11 in human endometrium by estradiol and progesterone. J. Immunol. 173, 6760–6766 (2004).
   PubMed Web of Science ®Google Scholar
• Blois S, Ilarregui JM, Tometten Met al. A pivotal role for galectin-1 in fetal tolerance Nat. Med. 13, 1450–1457 (2007).
   PubMed Web of Science ®Google Scholar
• Thomas P. Characteristics of membrane progestin receptor alpha (mPRα) and progesterone membrane receptor component 1 IPGMRC1) and their roles in mediating rapid progestin actions. Front. Neuroendocrinol. 29, 292–312 (2008).
   PubMed Web of Science ®Google Scholar
• Migliaccio A, Piccolo D, Castoria Get al. Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO J. 17, 2008–1018 (1998).
   PubMed Web of Science ®Google Scholar
• Chien EJ, Liao CF, Chang CPet al. The non-genomic effects on NA(+)/H(+)-exchange 1 by progesterone and 20 alpha-hydroxyprogesterone in human T cells. J. Cell Physiol. 211, 544–550 (2007).
   PubMed Web of Science ®Google Scholar
• Xu X, Weaver Z, Linke SPet al. Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol. Cell 3, 389–395, (1999).
   PubMed Web of Science ®Google Scholar
• Fukasawa K, Choi T, Kuriyama R, Rulong S, Vande Woude GF. Abnormal centrosome amplification in the absence of p53. Science 271, 1744–1747, (1996).
   PubMed Web of Science ®Google Scholar
• Srivastava MD, Thomas A, Srivastava BI, Check JH. Expression and modulation of progesterone-induced blocking factor (PIBF) and innate immune factors in human leukemia cell lines by progesterone and mifepristone. Leuk. Lymphoma 48, 1610–1617, (2007).
   PubMed Web of Science ®Google Scholar
• Check JH, Nazari P, Goldberg J, Yuen W, Angotti D. A model for potential tumor immunotherapy based on knowledge of immune mechanisms responsible for spontaneous abortion. Med. Hypoth. 57, 337–343 (2001).
   PubMed Web of Science ®Google Scholar
• Check JH, Dix E, Sansoucie L. Support for the hypothesis that successful immunotherapy of various cancers can be achieved by inhibiting a progesterone associated immunomodulatory protein. Med. Hypoth. 72, 87–90 (2009).
   PubMed Web of Science ®Google Scholar
• Check JH, Cohen R, Rosenberg A, DiAntonio A, Sarumi M, Srivastava M. Evidence that the immunosuppressive effect of the progesterone-induced blocking factor (PIBF) inhibiting a host response against cancer cells is probably not by influencing gamma/delta T cells in the tumor microenvironment to secrete PIBF and thus inhibit natural killer cell activity and therefore is dissimilar to the pregnancy state. Presented at: ISIR 2013 Meeting, Boston, MA, USA 28 May-1 June 2013 abstract #P-13. Am. J. Reprod. Immunol. 69, 50–51 (2013).
   Google Scholar
• Lange CA, Shen T, Horwicz KB. Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. Proc. Natl Acad. Sci. USA 97, 1032–1037 (2000).
   PubMed Web of Science ®Google Scholar
• Cui X, Schiff R, Arpino G, Osborne CK, Lee AV. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J. Clin. Oncol. 23, 7721–7735 (2005).
   PubMed Web of Science ®Google Scholar
• Conneely OM, Jericevic BM, Lydon JP. Progesterone receptors in mammary gland development and tumorigenesis. J. Mammary Gland. Biol. Neoplasia. 8, 205–214 (2003).
   PubMed Web of Science ®Google Scholar
• Wei LI, Hawkins P, Baker C, Norris B, Sheridan LP, Quinn PG. An amino-terminal truncated progesterone receptor isoform, PRc, enhances progestin-induced transcriptional activity. Mol. Endocrinol. 10, 1379–1387 (1996).
   PubMed Web of Science ®Google Scholar
• Condon JC, Hardy DB, Kovaric K, Mendelson CR. Upregulation of the progesterone receptor (PR)-C isoform in laboring myometrium by activation of NK-&kappaB may contribute to the onset of labor through inhibition of PR function. Mol. Endocrinol. 20, 764–775 (2006).
   PubMedGoogle Scholar
• Daniel AR, Hagan CR, Lange CA. Progesterone receptor action: defining a role in breast cancer. Expert Rev. 6, 359–369 (2011).
   Google Scholar
• Friedman LS, Ostermeyer EA, Lynch EDet al. The search for BRCA1. Cancer Res. 54, 6374–6382 (1994).
   PubMed Web of Science ®Google Scholar
• Zheng L, Annab LA, Afshari CA, Lee WH, Boyer tG. BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor. Proc. Natl Acad. Sci. USA 98, 9587–9592 (2001).
   PubMed Web of Science ®Google Scholar
• Fan S, Wang J, Yuan Ret al. BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science 284, 1354–1356 (1999).
   PubMed Web of Science ®Google Scholar
• Ma Y, Katiyar P, Jones LPet al. The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells. Mol. Endocrinol. 20, 14–34 (2006).
   PubMed Web of Science ®Google Scholar
• Hashizume R, Fukuda M, Maeda Iet al. The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer derived mutation. J. Biol. Chem. 276, 14537–14540 (2001).
   PubMed Web of Science ®Google Scholar
• Baer R, Ludwig T. The BRCA1/BARD1 heterodimer a tumor suppressor complex with ubiquitin E3 ligase activity. Curr. Opin. Genet. Dev. 12, 86–91 (2002).
   PubMed Web of Science ®Google Scholar
• Calvo V, Beato M. BRCA1 counteracts progesterone action by ubiquitination leading to progesterone receptor degradation and epigenetic silencing of target promoters. Cancer Res. 71, 3422–3431 (2011).
   PubMed Web of Science ®Google Scholar
• Fan S, Ma YX, Wang Cet al. Role of direct interaction in BRCA1 inhibition of estrogen receptor activity. Oncogene 20, 77–87 (2001).
   PubMed Web of Science ®Google Scholar
• Esteva FJ, Hortobagvi GN. Prognostic molecular markers in early breast cancer. Breast Cancer Res. 6, 109–118 (2004).
   PubMed Web of Science ®Google Scholar
• Payne SJ, Bowen RI, Jones JL, Wells CA. Predictive markers in breast cancer-the present. Histopathology 52, 82–90 (2008).
   PubMed Web of Science ®Google Scholar
• Grann VR, Troxel AB, Zojwalla NJ, Jacobson JS, Hershman D, Neugut AI. Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma. Cancer 103, 2241–2251 (2005).
   PubMed Web of Science ®Google Scholar
• Albert JM, Gonzalez-Angulo AM, Guray Met al. Patients with only 1 positive hormone receptor have increased locoregional recurrence compared with patients with estrogen receptor-positive progesterone receptor-positive disease in very early stage breast cancer. Cancer 15, 1595–1601 (2011).
   Google Scholar
• Graham JD, Yeates C, Balleine RIet al. Characterization of progesterone receptor A and B expression in human breast cancer. Cancer Res. 55, 5063–5068 (1995).
   PubMed Web of Science ®Google Scholar
• Mote PA, Bartow S, Tran N, Clarke CL. Loss of co-ordinate expression of progesterone receptors A and B is an early event in breast carcinogenesis. Breast Cancer Res. Treat. 72, 163–173 (2002).
   PubMed Web of Science ®Google Scholar
• Jones GS, Poumand K. An evaluation of etiologic factors and therapy in 555 private patients with primary infertility. Fertil. Steril. 13, 398 (1962).
   PubMed Web of Science ®Google Scholar
• Quagliarello J, Weiss G. Clomiphene citrate in the management of infertility associated with shortened luteal phases. Fertil. Steril. 31, 373 (1979).
   PubMed Web of Science ®Google Scholar
• Downs KA, Gibson M. Clomiphene citrate therapy for luteal phase defect. Fertil. Steril. 39, 34 (1983).
   PubMed Web of Science ®Google Scholar
• Check JH, Nowroozi K, Wu CH, Adelson HG, Lauer C. Ovulation-inducing drugs versus progesterone therapy for infertility in patients with luteal phase defects. Int. J. Fertil. 33, 252–256 (1988).
   PubMedGoogle Scholar
• Check JH, Liss J, Check D. The beneficial effect of luteal phase support on pregnancy rates in women with unexplained infertility. Fertil. Steril. 99(3), S23 (2013).
   PubMed Web of Science ®Google Scholar
• Guzick DS, Sullivan MW, Adamson GDet al. Efficacy of treatment for unexplained infertility. Fertil. Steril. 70, 207–213 (1998).
   PubMed Web of Science ®Google Scholar
• Bjuresten K, Landgren BM, Hovatta O, Stavreus-Evers A. Luteal phase progesterone increases live birth rate after frozen embryo transfer. Fertil. Steril. 95, 534–537 (2011).
   PubMed Web of Science ®Google Scholar
• Sonntag B, Ludwig M. An integrated view on the luteal phase: diagnosis and treatment in subfertility. Clin. Endocrinol. 77, 500–507 (2012).
   PubMed Web of Science ®Google Scholar
• Kerin JF, Broom TJ, Ralph MMet al. Human luteal phase function following oocyte cycles. Br. J. Obstet. Gynecol. 88, 1021–1028 (1981).
   PubMedGoogle Scholar
• Edwards RG, Steptoe PC, Purdy JM. Establishing full-term human pregnancies using cleaving embryos grown in vitro. Br. J. Obstet. Gynecol. 87, 737–756 (1980).
   PubMedGoogle Scholar
• Check JH, Wu CH, Adelson HG. Decreased abortions in hMG-induced pregnancies with prophylactic progesterone therapy. Int. J. Fertil. 30, 45–47 (1985).
   PubMedGoogle Scholar
• Check JH, Chase JS, Wu CH, Adelson HG, Teichman M, Rankin A. The efficacy of progesterone in achieving successful pregnancy: I. Prophylactic use during luteal phase in anovulatory women. Int. J. Fertil. 32, 135–138 (1987).
   PubMedGoogle Scholar
• van der Linden M, Buckingham K, Farquhar C, Kremer JAM, Metwally M. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst. Rev. (10), CD009154 (2011).
   PubMed Web of Science ®Google Scholar
• McAuley JW, Kroboth FJ, Kroboth PD. Oral administration of micronized progesterone: a review and more experience. Pharmacotherapy 16, 453–457 (1996).
   PubMed Web of Science ®Google Scholar
• Licciardi FL, Kwiatkowski A, Noyes NL, Merkeley AS, Krey LL, Grifo JA. Oral versus intramuscular progesterone for in vitro fertilization: a prospective randomized study. Fertil. Steril. 71, 614–618 (1999).
   PubMed Web of Science ®Google Scholar
• Check JH, Chase JS, Nowroozi K, Wu C. Spontaneous abortion rate in patients with endometriosis treated with progesterone. Int. J. Fertil. 32, 366–368 (1987).
   PubMedGoogle Scholar
• Nowroozi K, Chase JS, Check JH, Wu CH. The importance of laparoscopic coagulation of mild endometriosis in infertile women. Int. J. Fertil. 32, 442–444 (1987).
   PubMedGoogle Scholar
• Check JH. The association of minimal and mild endometriosis without adhesions and infertility with therapeutic strategies. Clin. Exp. Obst. Gyn. 30(1), 13–8 (2003).
   PubMedGoogle Scholar
• Cspo AI, Pukkinen M. Indispensability of the human corpus luteum in the maintenance of early pregnancy: lutectomy evidence. Obstet. Gynecol. Surv. 3, 69 (1978).
   Google Scholar
• Herman W, Wyss R, Riondel Aet al. Effects of an anti-progestin steroid in women: interruption of the menstrual cycle or early pregnancy (author’s transl). Contracept. Fertil. Sex. 10, 389–393 (1982).
   Google Scholar
• Yeko TR, Gorrill MJ, Hughes MH, Rodi IA, Buster JE, Sauer MV. Timely diagnosis of early ectopic pregnancy using a single blood progesterone measurement. Fertil. Steril. 48, 1048–1050 (1987).
   PubMed Web of Science ®Google Scholar
• Check JH, Winkel CA, Check ML. Abortion rate in progesterone treated women presenting initially with low first trimester serum progesterone levels. Am. J. Gynecol. Health 4, 33–34 (1990).
   Google Scholar
• Choe JK, Check JH, Nowroozi K, Benveniste R, Barnea ER. Serum progesterone and 17-hydroxyprogesterone in the diagnosis of ectopic pregnancies and the value of progesterone replacement in intrauterine pregnancies when serum progesterone levels are low. Gynecol. Obstet. Invest. 34, 133–138 (1992).
   PubMed Web of Science ®Google Scholar
• Fazleabas AT. Progesterone resistance in baboon model of endometriosis. Semin Reprod Med 28, 75–80 (2010).
   PubMed Web of Science ®Google Scholar
• Jackson KS, Brudney A, Hastings JM, Mavroginis PA, Kim JJ, Fazleabas AT. The altered distribution of the steroid hormone receptors and the chaperone immunophilin FKBP52 in a baboon model of endometriosis is associated with progesterone resistance during the window of uterine receptivity. Reprod. Sci. 14, 137–150 (2007).
   PubMed Web of Science ®Google Scholar
• Wahabi HA, Fayed AA, Esmaeil SA, Al Zeidan RA. Progestogen for treating threatened miscarriage. Cochrane Database Syst. Rev. (12), CD005943 (2011).
   PubMedGoogle Scholar
• Di Renzo GC, Giardina I, Clerici G, Mattei A, Alajmi AH, Gerli S. The role of progesterone in maternal and fetal medicine. Gynecol. Endoc. 28, 925–932 (2012).
   PubMed Web of Science ®Google Scholar
• Check JH, Lee G, Epstein R, Vetter B. Increased rate of preterm deliveries in untreated women with luteal phase deficiencies. Gynecol. Obstet. Invest. 33, 183–184 (1992).
   PubMed Web of Science ®Google Scholar
• Howritz KB. The structure and function of progesterone receptors in breast cancer. J. Steroid Biochem. 27, 447–457 (1987).
   PubMedGoogle Scholar
• Horwitz KB, McGuire WL. Predicting response to endocrine therapy in human breast cancer: a hypothesis. Science 189, 726–727 (1975).
   PubMed Web of Science ®Google Scholar
• Ramieu G, Maudelonde T, Ulmann Aet al. The antiprogestin RU486 in advanced breast cancer: preliminary clinical trial. Bull. Cancer 74, 455–461 (1987).
   PubMed Web of Science ®Google Scholar
• Klijn JG, de Jong FH, Bakker GH, Lamberts SW, Rodenburg CJ, Alexieva-Figusch J. Antiprogestins, a new form of endocrine therapy for human breast cancer. Cancer Res. 49, 2851–2856 (1989).
   PubMed Web of Science ®Google Scholar
• Robertson JF, Willsher PC, Winterbottom L, Blamey RW, Thorpe S. Onapristone, a progesterone receptor antagonist, as first-line therapy in primary breast cancer. Eur. J. Cancer 35, 214–218 (1999).
   PubMed Web of Science ®Google Scholar
• Check JH, Sansoucie L, Chern J, Amadi N, Katz Y. Mifepristone treatment improves length and quality of survival of mice with spontaneous leukemia. Anticancer Res. 29(8), 2977–2980 (2009).
   PubMed Web of Science ®Google Scholar
• Check JH, Sansoucie L, Chern J, Dix E. Mifepristone treatment improves length and quality of survival of mice with spontaneous lung cancer. Anticancer Res. 30, 119–122 (2010).
   PubMed Web of Science ®Google Scholar
• Check JH, Dix E, Wilson C, Check D. Progesterone receptor antagonist therapy has therapeutic potential even in cancer restricted to males as evidenced from murine testicular and prostate cancer studies. Anticancer Res. 30, 4921–4923 (2010).
   PubMed Web of Science ®Google Scholar
• Check JH, Dix E, Sansoucie L, Check D. Mifepristone may halt progression of extensively metastatic human adenocarcinoma of the colon–case report. Anticancer Res. 29(5), 1611–1613 (2009).
   PubMed Web of Science ®Google Scholar
• Check JH, Dix E, Cohen R, Check D, Wilson C. Efficacy of the progesterone receptor antagonist mifepristone for palliative therapy of patients with a variety of advanced cancer types. Anticancer Res. 30, 623–628 (2010).
   PubMed Web of Science ®Google Scholar
• Check JH, DiAntonio A, Check Det al. Clinical improvement of symptomatic advancing chronic lymphocytic leukemia following mifepristone therapy despite normal serum levels of the immunomodulatory protein the progesterone-induced blocking factor (PIBF). American Association for Cancer Research Annual Meeting.Washington, DC, 6–10 April 2013.
   Google Scholar
• Check JH, Wilson C, Check D. Evidence that mifepristone, a progesterone receptor antagonist, can cross the blood brain barrier and provide palliative benefits for glioblastoma multiforme grade IV. American Association for Cancer Research Annual Meeting.Washington, DC, 6–10 April 2013.
   Google Scholar
• Lai JN, Wang OY, Lin VH, Liao CF, Tarng DC, Chien EJ. The non-genomic rapid acidification in peripheral T cells by progesterone depends on intracellular calcium increase and not an Na+/H+-exchange inhibition. Steroids 77, 1017–1024 (2012).
   PubMed Web of Science ®Google Scholar
• Falkenstein E, Norman AW, Wehling M. Mannheim classification of nongenomically initiated (rapid) steroid action(s). J. Clin. Endocrinol. Metab. 85, 2072–2075 (2000).
   PubMed Web of Science ®Google Scholar
• Chien CH, Lai JN, Liao CFet al. Mifepristone acts as progesterone antagonist of non-genomic responses but inhibits phytohemagglutinin-induced proliferation in human T cells. Hum. Reprod. 24, 1968–1975 (2009).
   PubMed Web of Science ®Google Scholar
• Van Voorhis BJ, Anderson DJ, Hill JA. The effects of RU 486 on immune function and steroid-induced immunosuppression in vitro. J. Clin. Endocrinol. Metab. 69, 1195–1199 (1989).
   PubMed Web of Science ®Google Scholar
• Garrido-Gomez T, Ruiz-Alonso M, Blesa D, Diaz-Gimeno P, Vilella F, Simon C. Profiling the gene signature of endometrial receptivity: clinical results. Fertil. Steril. 99, 1078–1085 (2013).
   PubMed Web of Science ®Google Scholar
• Diaz-Gimeno P, Horcajadas JA, Martinez-Conejero JAet al. A genomic diagnostic tool for human endometrial receptivity based on the transcriptomic signature. Fertil. Steril. 95, 50–60 (2011).
   PubMed Web of Science ®Google Scholar
• Diaz-Gimeno P, Ruiz-Alanso M, Blesa Det al. The accuracy and reproducibility of the endometrial receptivity array is superior to histology as a diagnostic method for endometrial receptivity. Fertil. Steril. 99, 508–517 (2013).
   PubMed Web of Science ®Google Scholar
• Evans GE, Martinez-Conejero JA, Phillipson GTMet al. Gene and protein expression signature of endometrial glandular and stromal compartments during the window of implantation. Fertil. Steril. 97, 1365–1373 (2012).
   PubMed Web of Science ®Google Scholar
• Check JH, Choe JK, Katsoff D, Summers-Chase D, Wilson C. Controlled ovarian hyperstimulation adversely affects implantation following in vitro fertilization-embryo transfer. J. Assist. Reprod. Genet. 16, 416–420 (1999).
   PubMed Web of Science ®Google Scholar
• Check JH, Choe JK, Nazari A, Summers-Chase D. Ovarian hyperstimulation can reduce uterine receptivity. A case report. Clin. Exp. Obst. Gyn. 27(2), 89–91 (2000).
   PubMedGoogle Scholar
• Check JH, Check ML. A case report demonstrating that follicle maturing drugs may create an adverse uterine environment even when not used for controlled ovarian hyperstimulation. Clin. Exp. Obst. Gyn. 28, 217–218 (2001).
   PubMedGoogle Scholar
• Check JH. Minimal and natural stimulations for IVF. In: Advances in Embryo Transfer Chapter 2. Wu B (Ed.). InTech, Rejeka, Croatia, 21–36 (2012).
   Google Scholar
• Farhi J, Weissman A, Steinfeld Z, Shorer M, Nahum H, Levran D. Estradiol supplementation during the luteal phase may improve the pregnancy rate in patients undergoing in vitro fertilization-embryo transfer cycles. Fertil. Steril. 73, 73: 761–766 (2000).
   PubMedGoogle Scholar
• Lukaszuk K, Liss J, Kukaszuk M, Maj B. Optimization of estradiol supplementation during the luteal phase improves the pregnancy rate in women undergoing in vitro fertilization-embryo transfer cycles. Fertil. Steril. 83, 1372–1376 (2005).
   PubMed Web of Science ®Google Scholar
• Friedler S, Gilboa S, Schachter M, Raziel A, Strassburger D, Ron El R. Luteal phase characteristics following GnRH antagonist or agonist treatment–a comparative study. Reprod. Biomed. Online 12, 27–32 (2006).
   PubMed Web of Science ®Google Scholar
• Smitz J, Bourgain C, Van Waesberghe L, Camus M, Devroey P, Van Steirteghem AC. A prospective randomized study on oestradiol valerate supplementation in addition to intravaginal micronized progesterone in buserelin and HMG induced superovulation. Hum. Reprod. 8, 40–45 (1993).
   PubMed Web of Science ®Google Scholar
• Check JH, Tarquini P, Gandy P, Lauer C. A randomized study comparing the efficacy of reducing the spontaneous abortion rate following lymphocyte immunotherapy and progesterone treatment versus progesterone alone in primary habitual aborters. Gynecol. Obstet. Invest. 39, 257–261 (1995).
   PubMed Web of Science ®Google Scholar
• Cohen R, Check JH. Recurrent aneuploidy–fact of fiction. Clin. Exp. Obst. Gyn. 37, 175–177 (2010).
   PubMed Web of Science ®Google Scholar
• Check JH. The importance of up and down regulation of receptors for FSH, progesterone and the gonadotropin releasing hormone (GnRH) in the ovary, endometrium and lymphocytes in correcting various ovulatory disorders and achieving live deliveries. In: Ovulation: Detection Sign/Symptoms and Outcomes. De Lange K, Deguire E (Eds). Nova Science Publishers, Inc., Hauppauge, NY, (In press).
   Google Scholar
• Stadtmauer L, Silverberg KM, Ginsburg ES, Weiss H, Howard B. Progesterone vaginal ring versus vaginal gel for luteal support with in vitro fertilization: a randomized comparative study. Fertil. Steril. 99, 1543–1549 (2013).
   PubMed Web of Science ®Google Scholar
• Ganesh A, Chakravorty N, Mukherjee R, Goswami S, Chaudhury K, Chakravarty B. Comparison of oral dydrogesterone with progesterone gel and micronized progesterone for luteal support in 1,373 women undergoing in vitro fertilization: a randomized clinical study. Fertil. Steril. 95, 1961–1965 (2011).
   PubMed Web of Science ®Google Scholar
• Lanari C, Wargon V, Rojas P, Molinolo AA. Antiprogestins in breast cancer treatment are we ready? Endo. Rel. Cancer19, R35–R50 (2012).
   Web of Science ®Google Scholar
• Afhuppe W, Beckman JM, Otto Cet al. in vitro characterization of ZK 230211–a type III progesterone receptor antagonist with enhanced antiproliferative properties. J. Steroid. Biochem. Mol. Biol. 119, 45–55 (2010).
   PubMed Web of Science ®Google Scholar
• Chwalisz K, Brenner RM, Fuhrmann UU, Hess-Stumpp H, Elger W. Antiproliferative effects of progesterone antagonists and progesterone receptor modulators on the endometrium. Steroids 65, 741–751 (2000).
   PubMed Web of Science ®Google Scholar